Article (Scientific journals)
The benefits, costs and feasibility of a low incidence COVID-19 strategy
Czypionka, T.; Iftekhar, E.; Prainsack, B. et al.
2021In The Lancet Regional Health - Europe, 12 (100193)
Peer reviewed
 

Files


Full Text
1-s2.0-S2666776221002805-main.pdf
Publisher postprint (507.95 kB)
Download

The original publication is available at: https://doi.org/10.1016/j.lanepe.2021.100294


All documents in ORBilu are protected by a user license.

Send to



Details



Keywords :
COVID-19; SARS-CoV-2; pandemic; Public health strategies; non-pharmaceutical interventions; containment
Abstract :
[en] In the summer of 2021, European governments removed most NPIs after experiencing prolonged second and third waves of the COVID-19 pandemic. Most countries failed to achieve immunization rates high enough to avoid resurgence of the virus. Public health strategies for autumn and winter 2021 have ranged from countries aiming at low incidence by re-introducing NPIs to accepting high incidence levels. However, such high incidence strategies almost certainly lead to the very consequences that they seek to avoid: restrictions that harm people and economies. At high incidence, the important pandemic containment measure ‘test-trace-isolate-support’ becomes inefficient. At that point, the spread of SARS-CoV-2 and its numerous harmful consequences can likely only be controlled through restrictions. We argue that all European countries need to pursue a low incidence strategy in a coordinated manner. Such an endeavour can only be successful if it is built on open communication and trust.
Research center :
Luxembourg Centre for Systems Biomedicine (LCSB)
Disciplines :
Immunology & infectious disease
Life sciences: Multidisciplinary, general & others
Author, co-author :
Czypionka, T.
Iftekhar, E.
Prainsack, B.
Priesemann, V.
Bauer, S.
Valdez, A. C.
Cuschieri, S.
Glaab, Enrico  ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Biomedical Data Science
Grill, E.
Krutzinna, J.
Lionis, C.
Machado, H.
Martins, C.
Pavlakis, G.
Perc, M.
Petelos, E.
Pickersgill, M.
Skupin, Alexander  ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Integrative Cell Signalling
Schernhammer, E.
Szczurek, E.
Tsiodras, S.
Willeit, P.
Wilmes, Paul ;  University of Luxembourg > Luxembourg Centre for Systems Biomedicine (LCSB) > Systems Ecology
More authors (13 more) Less
External co-authors :
yes
Language :
English
Title :
The benefits, costs and feasibility of a low incidence COVID-19 strategy
Publication date :
2021
Journal title :
The Lancet Regional Health - Europe
Volume :
12
Issue :
100193
Peer reviewed :
Peer reviewed
Focus Area :
Systems Biomedicine
European Projects :
H2020 - 115910 - PERISCOPE - PERtussIS COrrelates of Protection Europe - Sofia ref.: 115910
FnR Project :
FNR14715687 - Combined In Silico Molecular Docking And In Vitro Experimental Assessment Of Drug Repurposing Candidates For Covid-19, 2020 (01/06/2020-30/11/2020) - Enrico Glaab
Name of the research project :
PERISCOPE
Funders :
CE - Commission Européenne [BE]
FNR - Fonds National de la Recherche [LU]
Available on ORBilu :
since 01 March 2022

Statistics


Number of views
122 (4 by Unilu)
Number of downloads
17 (0 by Unilu)

Scopus citations®
 
23
Scopus citations®
without self-citations
21
OpenCitations
 
6
WoS citations
 
21

Bibliography


Similar publications



Contact ORBilu